Among the opportunities that Linde could seize are its increasing investments in research and development with the aim of offering alternatives to carcinogenic solvents. These innovations should enable the group to attract new customers and improve its brand image.
Linde Group's share capital is currently split between a large proportion of free float and freely traded capital and another proportion held by private investors including The Vanguard Group with 8.06%, SSgA Funds Management with 4.09%, Norges Bank Investment Management with 3. 04%, Capital Research & Management with 3.01%, Massachusettes Financial Services with 2.62%, Blackrock Fund Advisors with 2.42%, T Row Price Associate with 2.19%, Fidelity Management & Research with 1.90%, Capital Research & Management World Investors with 1.79% and Barclays Bank with 1.56%.